secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001171843-25-005076
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Q2 net income $2.5M; revenue $10.7M; Dr. Sawhney joins Board
--------------------------------------------------------------------

- Q2 net income of $2.5M ($0.01 per share) vs loss of $19.8M in Q2 2024; total revenue $10.7M, up from $1.7M.
- Revenue increase primarily due to recognition of deferred revenue from termination of Qilu partnership; cash and equivalents $98.1M.
- Dr. Roger Sawhney appointed to Board effective Aug 4, 2025, succeeding Anuj Hasija who resigned to join Vertex.
- In Moderna U.S. litigation, summary judgment phase began July 2025; jury trial scheduled March 2026.
- R&D expenses down to $5.5M from $15.6M due to restructuring; G&A down to $3.3M from $7.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325005076/0001171843-25-005076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325005076/f8k_080625.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer